Intelerad Medical Systems recenlty announced that Australia’s Primary Health Care Limited (Primary) has selected Intelerad’s InteleOne XE as the enterprise imaging platform for its diagnostic imaging division, Healthcare Imaging Services (HIS). Together with the Nuance PowerScribe 360 Reporting platform, InteleOne XE will provide a consolidated archive and unified workflow, allowing the nationwide organization’s 141 sites to operate as a single entity.

Visage Imaging Inc. announced that Mercy, the fifth largest Catholic health system in the United States, completed its enterprise-wide implementation of the Visage 7 Enterprise Imaging Platform in record time. Visage 7 enables enterprise imaging with fast, thin-client, server-side processing technology, as well as simple diagnostic mobile access via Visage Ease Pro.

EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU (high-intensity focused ultrasound) for prostate tissue ablation in patients who had previously undergone radiotherapy treatment. The article concludes that HIFU should be considered as a valuable therapeutic option for carefully selected patients who failed a previous radiotherapy treatment. The article was published in the January 2017 edition of the British Journal of Urology International.

Results from a prospective clinical trial showed a blood test looking at specific biomarkers was able to detect lung cancer recurrences an average of six months before conventional imaging methods found evidence of recurrence. In the largest prospective clinical trial to date of circulating tumor cells (CTC) as biomarkers for locally advanced lung cancer, the findings indicate that blood tests potentially can be used in conjunction with computed tomography (CT) and positron emission tomography (PET)/CT scans to guide personalized treatment planning for patients with non-small cell lung cancer (NSCLC). The study was presented at the 2017 Multidisciplinary Thoracic Cancers Symposium, March 16-18 in San Diego.